Marina Vilardo

Marina Vilardo

Auto-generated profile, based on publicly available information

Marina Vilardo

Department of Neurology, Massachusetts General Hospital, Boston, Massachusetts, USA

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 March 2025 in Stroke
Verified
Journal Article
Closed access
AGAhmet Günkan
Ahmet Günkan
MFMarcio Yuri Ferreira
Marcio Yuri Ferreira
MVMarina Vilardo
Marina Vilardo
LSLuca Scarcia
Luca Scarcia
JBJhon E. Bocanegra-Becerra
Jhon E. Bocanegra-Becerra
Claude BaronClaude Baron
Claude Baron
BACKGROUND: A minority of patients with stroke qualify for intravenous thrombolysis (IVT) within 4.5-hour window. The safety and efficacy of IVT beyond this period have not been well studied. METHODS: We systematically searched MEDLINE, Embase, Cochrane, and ClinicalTrials.gov for relevant randomized clinical trials. Randomized clinical trials comparing IVT versus standard medical care in patients with ischemic stroke beyond 4.5 hours of symptom onset or last known well without mechanical thrombectomy (MT) were included. Primary outcomes were excellent (modified Rankin Scale score of 0–1) and good (modified Rankin Scale score of 0–2) functional outcomes at 90 days, symptomatic intracerebral hemorrhage (sICH), and death at 90 days. Pooled odds ratios (ORs) with 95% CIs were calculated using a random-effects model. Heterogeneity was assessed by Q test and quantified by I ² values. RESULTS: Eight randomized clinical trials (1742 patients; mean age, 69.8±9 years, 63.5% men) were included. Compared with standard medical care, IVT achieved higher rates of excellent (OR, 1.43 [95% CI, 1.17–1.75]; Q =2.30; P =0.94; I 2 =0%) and good functional outcomes (OR, 1.36 [95% CI, 1.12–1.66]; Q =2.07; P =0.96; I 2 =0%) at 90 days but also increased sICH rates (OR, 4.25 [95% CI, 1.67–10.84], Q =0.48; P =0.99; I 2 =0%). Mortality at 90 days did not significantly differ between treatment groups (OR, 1.28 [95% CI, 0.87–1.89]; Q =4.63; P =0.59; I 2 =0%). Subanalyses yielded numerically higher odds of excellent functional outcomes when patients were selected with perfusion imaging (3 studies, OR, 1.45 [95% CI, 1.08–1.94]) compared with diffusion-weighted imaging–fluid-attenuated inversion recovery mismatch (3 studies, OR, 1.34 [95% CI, 0.94–1.91]) and when treated with tenecteplase (3 studies, OR, 1.47 [95% CI, 1.06–2.04]) compared with alteplase (5 studies, OR, 1.38 [95% CI, 1.08–1.78]). CONCLUSIONS: IVT for ischemic stroke beyond 4.5 hours, without MT, led to increased odds of excellent and good functional outcomes compared with standard medical care, despite higher odds of sICH, and a nonsignificant numerical increase in mortality.

13 May 2025 in Journal of NeuroInterventional Surgery
Verified
Journal Article
Closed access
PDF file
AGAhmet Günkan
Ahmet Günkan
MVMarina Vilardo
Marina Vilardo
JSJoão Paulo Liute Scarramal
João Paulo Liute Scarramal
AEAlperen Elek
Alperen Elek
JBJhon E Bocanegra-Becerra
Jhon E Bocanegra-Becerra
LSLuca Scarcia
Luca Scarcia
Background Flow diverters (FDs) are increasingly used off-label for distal cerebral aneurysms (DCAs), those located at or beyond the anterior cerebral artery (ACA) A2, middle cerebral artery M2, and posterior cerebral artery P2 segments. However, data on their safety and efficacy remain limited. This systematic review and meta-analysis synthesizes current evidence on FD treatment for DCAs. Methods A comprehensive search was performed across PubMed, Scopus, and Web of Science, including studies with ≥5 patients reporting FD treatment of DCAs. Efficacy outcomes included adequate and complete aneurysm occlusion and retreatment rates. Safety outcomes included good functional outcome (modified Rankin Scale (mRS) score 0–2), procedure-related morbidity, mortality, complications, in-stent stenosis, and covered branch occlusion at follow-up. Pooled analyses with 95% confidence intervals (CI) were conducted using a random-effects model. Results Eighteen studies (441 patients, 70% women; mean age: 57.2±13.6 years) with 445 DCAs were included. Most aneurysms were unruptured (93.7%) and located in the ACA territory (78.4%). Adequate and complete occlusion at last follow-up were 90% (95% CI, 86 to 95) and 79% (95% CI, 74 to 85), respectively. The retreatment rate was 1.6% (95% CI, 0.2 to 3). Good functional outcome was achieved in 97% (95% CI, 95 to 99). Procedure-related complications occurred in 9% (95% CI, 5 to 13), with morbidity and mortality of 1.5% and 0.6%, respectively. In-stent stenosis and covered branch occlusion rates were 3% (95% CI, 0 to 8) and 5.5% (95% CI, 2 to 9), respectively. Conclusion FDs appear to be safe and effective for DCAs, with high occlusion rates and low retreatment and complication rates.

26 June 2023 in Abdominal Radiology
Verified
Journal Article
Closed access
PDF file
CJCarlos Alberto Campello Jorge
Carlos Alberto Campello Jorge
ECEverton Bruno Castanha
Everton Bruno Castanha
MVMarina Vilardo
Marina Vilardo
PSPedro V. Staziaki
Pedro V. Staziaki
MFMartina Zaguini Francisco
Martina Zaguini Francisco
SAStephan Altmayer
Stephan Altmayer

17 October 2024 in Interventional Neuroradiology
Verified
Journal Article
Closed access
AGAhmet Günkan
Ahmet Günkan
MFMarcio Yuri Ferreira
Marcio Yuri Ferreira
MVMarina Vilardo
Marina Vilardo
LSLuca Scarcia
Luca Scarcia
JBJhon E. Bocanegra-Becerra
Jhon E. Bocanegra-Becerra
YSYafell Serulle
Yafell Serulle
Background: A wide range of liquid embolic agents has been used in endovascular treatment (EVT) of dural arteriovenous fistulas (dAVFs) and cerebral arteriovenous malformations (cAVMs). Newer liquid embolics, Squid (Balt) and PHIL (MicroVention), aim to improve the safety and efficacy of EVT of dAVFs and cAVMs. Objective: To assess the safety and efficacy of EVT of cAVMs and dAVFs using Squid or PHIL as an embolic agent. Methods: We searched major databases following PRISMA guidelines and included studies with ≥ five patients reporting on EVT of dAVFs and/or cAVMs using Squid or PHIL as embolic agent. We analyzed efficacy outcomes including complete occlusion, incomplete occlusion, and recurrence at follow up, and safety outcomes including procedure-related complications, morbidity, and mortality with a random-effects meta-analysis. Separate analyses were performed for cAVMs and dAVFs. Subanalyses were conducted for studies exclusively utilizing PHIL and those exclusively utilizing Squid, for both cAVMs and dAVFs. Results: Ten studies, comprising 214 patients (53.7% male), were found. Of these, 113 patients had 113 dAVFs, while 101 patients had 101 cAVMs. Complete occlusion rates following embolization were 91% for dAVFs and 32% for cAVMs. A subanalysis of dAVFs embolized solely with Squid and PHIL identified 93% and 86% complete occlusion rates, respectively. The overall procedure-related permanent morbidity rate was 3% for dAVFs and 7% for cAVMs. There was only one procedure-related mortality, which developed in a cAVM case, across 214 cases. Conclusion: Squid and PHIL are safe and effective embolic agents for treatment of dAVFs and cAVMs.

14 August 2024 in World Neurosurgery
Verified
Journal Article
Closed access
LPLucca B Palavani
Lucca B Palavani
RCRaphael Camerotte
Raphael Camerotte
LMLucas Pari Mitre
Lucas Pari Mitre
SBSávio Batista
Sávio Batista
IBIsabela Banderali
Isabela Banderali
Jean G. de OliveiraJean G. de Oliveira
Jean G. de Oliveira

28 August 2025 in American Journal of Neuroradiology
Verified
Journal Article
Closed access
PDF file
MVMarina Vilardo
Marina Vilardo
AGAhmet Günkan
Ahmet Günkan
Adam DmytriwAdam Dmytriw
Adam Dmytriw
AEAlperen Elek
Alperen Elek
JSJoão Paulo Liute Scarramal
João Paulo Liute Scarramal
LSLuca Scarcia
Luca Scarcia
BACKGROUND: Flow diverters (FDs) are increasingly used off-label for the treatment of distal anterior cerebral artery aneurysms (DACAAs), located at or beyond the A2 segment of the anterior cerebral artery (ACA). However, data on safety and efficacy remain limited. PURPOSE: To evaluate the safety and efficacy of FDs for the treatment of DACAAs through a systematic review and meta-analysis. DATA SOURCES: PubMed, Scopus, and Web of Science were systematically searched according to PRISMA guidelines. STUDY SELECTION: Studies were eligible if they reported on ≥5 patients treated with FDs for DACAAs and provided angiographic and clinical outcome data. DATA ANALYSIS: Efficacy outcomes included adequate and complete aneurysm occlusion rates and retreatment rates. Safety outcomes included good functional outcome (mRS 0–2), procedure-related morbidity and mortality, procedure-related complications, in-stent stenosis, and covered branch occlusion. Pooled estimates with 95% confidence intervals (CIs) were calculated using a random-effects model. DATA SYNTHESIS: Eleven retrospective studies comprising 326 patients (71% female; mean age, 59.4 ± 4.4 years) with 328 DACAAs were included. Most aneurysms were unruptured (95.7%) and located in the A2 or A2–A3 segments (89%). Adequate and complete occlusion at last follow-up were 89% (95% CI, 82–96) and 77% (95% CI, 69–85), respectively. The retreatment rate was 1% (95% CI, 0– 3). Good functional outcome was reported in 97% (95% CI, 95–100). Procedure-related complications occurred in 7% (95% CI, 1–12), resulting in 1% morbidity (95% CI, 0–3) and no procedure-related deaths. In-stent stenosis and covered branch occlusion were observed in 4% (95% CI, 0–10) and 10% (95% CI, 6–13), respectively. Clinically symptomatic covered branch occlusion was rare (1.1%), possibly reflecting the adequacy of collateral circulation in distal ACA territory. LIMITATIONS: The analysis is based on retrospective studies that lacked centralized adjudication of angiographic outcomes, potentially introducing methodological biases intrinsic to such study designs, including selection bias, confounding, and publication bias. CONCLUSIONS: FDs appear to be a safe and effective treatment option for DACAAs, with high rates of occlusion and favorable clinical outcomes, and low rates of retreatment and procedure-related complications. ABBREVIATIONS: ACA= anterior cerebral artery; DACAAs= distal anterior cerebral artery aneurysms; FDs= flow diverters.